#United States #New York #Class Action #Levi & Korsinsky #Altimmune

Attention Altimmune Investors

Levi & Korsinsky, LLP has officially alerted investors in Altimmune, Inc. (NASDAQ: ALT) regarding a pending class action securities lawsuit that may have serious implications for shareholders. The deadline to act as a lead plaintiff is set for October 6, 2025.

Overview of the Lawsuit

This class action lawsuit aims to recover losses for all Altimmune investors adversely impacted by alleged securities fraud occurring between August 10, 2023, and June 25, 2025. For those interested in learning more or participating, you can follow the link provided by Levi & Korsinsky to submit your details and seek legal contact.

Case Details

On June 26, 2025, Altimmune made public the topline results from its IMPACT Phase 2b MASH trial related to the drug Pemvidutide. Unfortunately for Altimmune, the results were disappointing, revealing the company failed to achieve statistical significance regarding the primary endpoint related to fibrosis reduction. Despite consistent communications leading up to the trial results that seemed to present optimistic scenarios, the actual outcomes were far less favorable.

Specifically, although there were signs of improvement in fibrosis, the results fell short of statistical significance due to unexpectedly high placebo responses. When asked about the lack of favorable results, company representatives offered a nonchalant explanation, attributing the disappointment to the nature of the Phase 2 trial and expressing hope for better results in future Phase 3 trials.

Following this news release, Altimmune's stock plummeted drastically, dropping from a closing price of $7.71 on June 25, 2025, to a mere $3.61 by the next day—a staggering decline of 53.2%. This monumental loss has prompted stakeholders to take action to seek justice and restoration of financial losses.

What You Should Do Next

If you have experienced financial setbacks due to your investments in Altimmune within the specified period, there’s still time to take action. You have until October 6, 2025, to request that the Court appoint you as the lead plaintiff in this case.

It's critical to note that participating as a lead plaintiff is not a prerequisite for shared recovery. If you qualify as a class member, you may be entitled to compensation without upfront costs or fees.

Why Choose Levi & Korsinsky?

Levi & Korsinsky boasts a remarkable record, having secured hundreds of millions of dollars for investors over the past two decades. Specializing in complex securities litigation, their accomplished team of over 70 professionals is devoted to advocating for the rights and compensation of aggrieved shareholders. Their strong reputation has consistently placed them among the top securities litigation firms in the U.S.

For more information and assistance on the ongoing case against Altimmune, interested parties may reach out to:

• - Joseph E. Levi, Esq.

33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500

Empowering investors to stand up for their rights is at the core of Levi & Korsinsky's mission. Don't miss this opportunity to pursue your claims and seek the justice you deserve.